Retrospective analysis of total direct medical costs associated with hepatitis B patients with oral antiviral versus pegylated interferon therapy in Turkey

Journal of Viral Hepatitis

Volumn 21, Issue 11, 2014, Pages 794-801

  Altinbas, A ^a   Baser, E ^b   Burkan, A ^c   Ertugay, E ^c   Kariburyo, M F ^b   Baser, O ^b  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b STATINMED RESEARCH   (United States)

^c Undersecretariat of Treasury   (Turkey)

Author keywords

hepatitis b; medical costs; outcomes research; real word data analysis

Indexed keywords

ANTIVIRUS AGENT; PEGINTERFERON; ALPHA INTERFERON;

ADULT; AGED; ARTICLE; DISEASE ASSOCIATION; ELIXHAUSER COMORBIDITY INDEX; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HEPATITIS B; HEPATITIS B VIRUS; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; MIDDLE AGED; OUTPATIENT CARE; PHARMACY; PRESCRIPTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SOUTHERN EUROPE; TURKEY (REPUBLIC); YOUNG ADULT; ADOLESCENT; ECONOMICS; ORAL DRUG ADMINISTRATION; TURKEY; VERY ELDERLY;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; FEMALE; HEALTH CARE COSTS; HEPATITIS B; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TURKEY; YOUNG ADULT;

EID: 84908049573     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12206     Document Type: Article

References (31)

1. Hepatitis B: Fact Sheet No: 204, 2012. Available at: http://www.who.int/mediacentre/factsheets/fs204/en/ (accessed 28 May 2012).
2. Toy M, Veldhuijzen IK, de Man RA, Richardus JH, Schalm SW,. Potential impact of long-term nucleoside therapy on the mortality and morbidity of active chronic hepatitis B. Hepatology 2009; 50: 743-751.
3. Toy M, Onder FO, Idilman R, et al,. The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country. Eur J Health Econ 2012; 13: 663-676.
4. Gurol E, Saban C, Oral O, Cigdem A, Armagan A,. Trends in hepatitis B and hepatitis C virus among blood donors over 16 years in Turkey. Eur J Epidemiol 2006; 21: 299-305.
5. Degertekin H, Gunes G,. Horizontal transmission of hepatitis B virus in Turkey. Public Health 2008; 122 (12): 1315-1317.
6. Altbox drawings light down and leftnbas S, Erdogan M, Danbox drawings light down and leftşman N,. The seroprevalences of HBs Ag and anti-HCV in pregnant women in Ankara. Arch Gynecol Obstet 2010; 281 (2): 371.
7. Hepatitis B in Turkey. Ministry of Health, Turkey, 2013. Available at: http://www.vhpb.org/files/html/Meetings-and-publications/VHPB-Meetings/Kyiv2004/pdf/S41enUsta.pdf (accessed 29 May 2013).
8. Marcellin P, Castelnau C, Martinot-Peignoux M, Boyer N,. Natural history of hepatitis B. Minerva Gastroenterol Dietol 2005; 51 (1): 63-75.
9. Altinbas A, Yuksel I, Pamukcu M, Ekiz F, Basar O, Yuksel O,. Spontaneous HBsAg seroconversion after severe flare of chronic hepatitis B infection. Ann Hepatol 2010; 9 (2): 194-197.
10. Ergunay K, Balaban Y, Cosgun E, et al,. Epidemiologic trends in HBV infections at a reference centre in Turkey: an 11-year retrospective analysis. Ann Hepatol 2012; 11 (5): 672-678.
11. Ozer A, Yakupogullari Y, Beytur A, Beytur L, Koroglu M,. Risk factors of hepatitis B virus infection in turkey: a population-based, case-control study: risk factors for HBV infection. Hepat Mon 2011; 11 (4): 263-268.
12. Kim W,. Epidemiology of hepatitis B in the United States. Hepatology 2009; 49: S28-S34.
13. Akarsu M, Matur M, Karademir S, Unek T, Astarcioglu I,. Cost analysis of liver transplantation in Turkey. Transplant Proc 2011; 43 (10): 3783-3788.
14. Hatzakis A, Wait S, Bruix J, et al,. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J Viral Hepat 2011; 18 (Suppl 1): 1-16.
15. Chien RN, Liaw YF,. Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success. Best Pract Res Clin Gastroenterol 2008; 22 (6): 1081-1092.
16. Lau DT, Bleibel W,. Review: current status of antiviral therapy for hepatitis B. Therap Adv Gastroenterol 2008; 1 (1): 61-75.
17. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A,. Direct medical costs associated with rheumatoid arthritis in Turkey: analysis from National Claims Database. Rheumatol Int 2013; 33 (10): 2577-2584.
18. Baser O, Baser E, Altinbas A, Burkan A,. Severity index for rheumatoid arthritis and its association with health care costs and biologic therapy use in Turkey. Health Econ Rev 2013; 3 (1): 5.
19. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A,. High cost patients for cardiac surgery and hospital quality in Turkey. Health Policy 2013; 109 (2): 143-149. Epub 2012 Oct 22.
20. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A,. Health care costs associated with ankylosing spondylitis in Turkey: an analysis from nationwide real-world data. Int J Rheumatol 2013; 2013: 139608. Epub 2013 Feb 19.
21. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A,. Coronary angiography utilization and costs for coronary artery bypass graft surgery patients in Turkey. Cardiol Ther 2013; 2 (2): doi: 10.1007/s40119-013-0018-z
22. Elixhauser A, Steiner C, Harris DR, Coffey RM,. Comorbidity measures for use with administrative data. Med Care 1998; 36: 8-27.
23. Baser O, Palmer L, Stephenson J,. The estimation power of alternative comorbidity indices. Value Health 2008; 11: 946-955.
24. Rubin DB,. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127 (8 pt 2): 757-763.
25. Baser O,. Too much ado about propensity score models? Comparing methods of propensity score matching. Value Health 2006; 9: 377-385.
26. Kanwal F, Gralnek IM, Martin P, Dulai GS, Farid M, Spiegel BM,. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med 2005; 142 (10): 821-831.
27. Kanwal F, Farid M, Martin P, et al,. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. Am J Gastroenterol 2006; 101 (9): 2076-2089.
28. Wong JB, Koff RS, Tinè F, Pauker SG,. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995; 122 (9): 664-675.
29. Shepherd J, Jones J, Takeda A, Davidson P, Price A,. Review Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Health Technol Assess 2006; 10 (28): iii-iv, xi-xiv, 1-183.
30. Buti M, Brosa M, Casado MA, Rueda M,. Esteban R Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. J Hepatol 2009; 51 (4): 640-646.
31. Veenstra DL, Sullivan SD, Dusheiko GM, et al,. Cost-effectiveness of peginterferon alpha-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom. Eur J Gastroenterol Hepatol 2007; 19 (8): 631-638.